A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Latest Information Update: 29 Aug 2023
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 20 Jul 2023 Results comparing BIN1 risk allele rs6733839 with APOE4 on interdependency among AD risk factors and biomarkers by applying Bayesian Network (BN) modeling to data from Lilly AD clinical trials (A05C (n=142, NCT01565382), A05E (n=217, NCT02016560), AZES (n=206, NCT02245737), LLCF (n=229, NCT02791191), and LZAX (n=194, NCT01900665) ), presented at the Alzheimer's Association International Conference 2023.
- 31 Jul 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.(End date:2018-10-02).
- 10 Jan 2019 This study has been completed in Poland.